Subtype
Lung Neuroendocrine Neoplasm
CI-CAN-00001096Explore in graph →
Non-malignant399 active trials6 approved drugs6 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001096Explore in graph →
Clinical trials
1,149 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07744256 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03896503 |
| Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs |
| active not recruiting |
| Phase 2 |
| 104 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 31, 2026 |
| clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05957510 | Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment | active not recruiting | Phase 2 | 66 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07339059 | Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 35 | Bindu R PotugariOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05882058 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | recruiting | Phase 2 | 204 | Boehringer IngelheimINDUSTRY | 12 | Jul 23, 2026 | clinicaltrials |
| NCT06437509 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 66 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05060016 | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)(DeLLphi-301) | active not recruiting | Phase 2 | 222 | AmgenINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT07253142 | A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer | recruiting | Phase 2 | 120 | Shanghai Henlius BiotechINDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07559786 | A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy(ARL-LS-SCLC) | recruiting | Phase 2 | 200 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05652686 | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | recruiting | Phase 1 / Phase 2 | 203 | Phanes TherapeuticsINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT07698054 | Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer | not yet recruiting | Phase 2 | 130 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 13, 2026 | clinicaltrials |
| NCT06502977 | Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment(DeLLphi-307) | active not recruiting | Phase 2 | 32 | AmgenINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07174583 | A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 262 | IDEAYA BiosciencesINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients(MERLIN) | recruiting | Phase 2 | 37 | Fundación GECPOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04745689 | Study of AZD2811 + Durvalumab in ES-SCLC(TAZMAN) | active not recruiting | Phase 2 | 31 | AstraZenecaINDUSTRY | 4 | Jul 6, 2026 | clinicaltrials |
| NCT07358676 | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 25 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07423585 | Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer | recruiting | Phase 2 | 39 | Asrar AlahmadiOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07149363 | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | recruiting | Phase 2 | 65 | Alliance Foundation Trials, LLC.OTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06227546 | MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer(MGC018-SCLC) | active not recruiting | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03110978 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer(LOTS) | recruiting | Phase 1 / Phase 2 | 16 | Misty ShieldsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07508852 | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Peking University First HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01638546 | Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer | active not recruiting | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT06501976 | An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment | active not recruiting | Phase 2 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04728230 | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | active not recruiting | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07091305 | A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy | recruiting | Phase 2 | 28 | Shanghai Chest HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05419076 | A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 0 | Jun 9, 2026 | clinicaltrials |
| NCT06497530 | Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC | recruiting | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | not yet recruiting | Phase 2 | 227 | GV20 TherapeuticsINDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632209 | Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment(Aurora003) | not yet recruiting | Phase 2 | 46 | Yayi HeOTHER | 0 | Jun 8, 2026 | clinicaltrials |
| NCT04334941 | Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker | active not recruiting | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06771518 | Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab | recruiting | Phase 2 | 37 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) | active not recruiting | Phase 1 / Phase 2 | 110 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Jun 1, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | recruiting | Phase 2 | 280 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06812260 | A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC | active not recruiting | Phase 2 | 26 | Shanghai Henlius BiotechINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT07583511 | Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study | recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05092412 | Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC | active not recruiting | Phase 2 | 30 | You LuOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05363280 | Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment | recruiting | Phase 2 | 80 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT07296809 | SKB500 Combinations in Patients With Small Cell Lung Cancer | recruiting | Phase 2 | 80 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04553133 | PF-07104091 as a Single Agent and in Combination Therapy | active not recruiting | Phase 2 | 157 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT06217757 | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | recruiting | Phase 1 / Phase 2 | 45 | Sichuan UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05765825 | Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC | active not recruiting | Phase 2 | 61 | Sichuan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05903092 | MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer(MOZART) | recruiting | Phase 2 | 84 | Hirva MamdaniOTHER | 1 | Apr 29, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2026source: clinicaltrials